<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373735</url>
  </required_header>
  <id_info>
    <org_study_id>S2014-2192</org_study_id>
    <nct_id>NCT02373735</nct_id>
  </id_info>
  <brief_title>Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes</brief_title>
  <official_title>Effect of Stroke Volume Variation Guided Fluid Therapy on the Blood Loss and Postoperative Outcomes in Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of stroke volume variation (SVV)
      guided fluid therapy on the blood loss and postoperative outcomes in radical cystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the effect of stroke volume variation(SVV) guided
      fluid therapy on the blood loss and postoperative outcomes in radical cystectomy. Patients
      were randomized to fluid management to maintain &lt;10% SVV (group A), or to undergo fluid
      management during radical cystectomy to maintain SVV 10-20% (group B). Intraoperative blood
      loss and hemodynamic parameters, perioperative laboratory data, and postoperative
      complications were compared between two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>During operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications (cardiovascular complications, gastrointestinal complications, pulmonary complications, renal complications, infection, death)</measure>
    <time_frame>During 30 days after operation</time_frame>
    <description>Postoperative complications include cardiovascular complications, gastrointestinal complications, pulmonary complications, renal complications, infection, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay/ICU stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Group A (SVV &lt;10% group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infuse crystalloid (Hartmann`s solution) 6-10 ml/kg/hr continuously during surgery
infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery
Interventions: crystalloid (Hartmann`s solution), colloid (Volulyte)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (SVV 10-20% group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infuse crystalloid (Hartmann`s solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
infuse colloid (Volulyte) 200 ml if SVV is &gt; 20%
infuse mannitol 0.5 g/kg or lasix 5 mg if SVV &lt; 10%
Interventions: crystalloid (Hartmann`s solution), colloid (Volulyte), mannitol, lasix</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>crystalloid</intervention_name>
    <description>Group A (SVV &lt;10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy</description>
    <arm_group_label>Group A (SVV &lt;10% group)</arm_group_label>
    <arm_group_label>Group B (SVV 10-20% group)</arm_group_label>
    <other_name>Hartmann`s solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>colloid</intervention_name>
    <description>Group A (SVV &lt;10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is &gt; 20%</description>
    <arm_group_label>Group A (SVV &lt;10% group)</arm_group_label>
    <arm_group_label>Group B (SVV 10-20% group)</arm_group_label>
    <other_name>volulyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mannitol</intervention_name>
    <description>Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is &lt; 10%</description>
    <arm_group_label>Group B (SVV 10-20% group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lasix</intervention_name>
    <description>Group B (SVV 10-20%): infuse lasix 5 mg if SVV is &lt; 10%</description>
    <arm_group_label>Group B (SVV 10-20% group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bladder cancer patients who received radical cystectomy

          -  Patients with American Society of Anesthesiologists physical status scale
             classification 1, 2

          -  Patients who agree with written informed consent

        Exclusion Criteria:

          -  Patients with history of arrhythmia, heart failure patients

          -  Patients with history of renal failure patients

          -  Patients with history of abdominal surgery

          -  Patients who received emergency operation

          -  Patients who do not agree with study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Kug Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Kug Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>stroke volume variation</keyword>
  <keyword>radical cystectomy</keyword>
  <keyword>blood loss</keyword>
  <keyword>postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

